Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Project

RUNX2 as a driver of poor prognostic early T-cell progenitor leukemia

Outputs and Outcomes

Code

3G065614

Duration

01 January 2014 → 31 December 2019

Funding

Research Foundation - Flanders (FWO)

Promotor

Hans Van Vlierberghe

Research disciplines

Medical and health sciences
- Cancer biology
- Cancer biology
- Cancer therapy

Keywords

runx2 genomics leukemia

Project description

The goal of this research proposal is to unravel the role of RUNX2 in the biology of a very poor prognostic subtype of human leukemia, ie. early T-cell progenitor (ETP) ALL. Given that these ETP-ALL patients completely fail current chemotherapy treatment, this project addresses the urgent need to identify new drugable targets for therapeutic intervention in this aggressive haematological malignancy.

English

Dutch

English

Cookie settings

In addition to functional cookies which are necessary for the website to function, Ghent University uses non-functional cookies such as statistical cookies and social media cookies. These non-functional cookies can also be placed by third parties, for example to measure the use of the site or to share content on social media. Certain media are only available if you accept the cookies. You can set and modify your cookie preferences yourself. Find out what cookies we use and why in the Cookie Statement.

Analytics

AnalyticsWe'll collect information about your visit to our site. It helps us understand how the site is used – what's working, what might be broken and what we should improve.

Powered by